Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients

Journal of Cellular Physiology

Volumn 227, Issue 6, 2012, Pages 2798-2803

  Ciarcia, Roberto ^a   Vitiello, Maria Teresa ^b   Galdiero, Massimiliano ^b   Pacilio, Carmen ^c   Iovane, Valentina ^a   D'Angelo, Danila ^a   Pagnini, David ^d   Caparrotti, Giuseppe ^d   Conti, Daniele ^e,f   Tomei, Valentina ^e   Florio, Salvatore ^a   Giordano, Antonio ^e,g  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d San Giuseppe Moscati Hospital   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

^f Human Health Foundation Onlus   (Italy)

^g Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; PURINERGIC RECEPTOR; TRANSCRIPTION FACTOR AP 1;

ADULT; ARTICLE; CALCIUM CELL LEVEL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; FEMALE; FOLLOW UP; HEMATOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; CALCIUM; CASE-CONTROL STUDIES; CELL MEMBRANE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOPLASMIC RETICULUM; FEMALE; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; INTERLEUKIN-6; INTERLEUKIN-8; ITALY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NF-KAPPA B; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, PURINERGIC; TRANSCRIPTION FACTOR AP-1; TREATMENT OUTCOME;

EID: 84857486102     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.23029     Document Type: Article

References (42)

1. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. 2003. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88:1721-1726.
2. Bass DA, Dechatelet LR, McCall CE. 1978. Independent stimulation of motility and theoxidative metabolic burst of human polymorphonuclear leukocytes. J Immunol 121:172-178.
3. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B. 2009. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119:1109-1123.
4. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. 2004. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103:3175-3184.
5. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. 2006. Targeting NF-kappaB in hematologic malignancies. Death Differ 13:748-758.
6. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB. 1996. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104.
7. Bueso-Ramos CE, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen MH, Aggarwal BB. 2004. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Human Pathol 35:246-253.
8. Cheng Y, Prusoff WF. 1973. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Chused TM, Apasov S, Sitkovsky MV. 1996. Murine T lymphocytes modulate activity of an ATP-activated P2Z-type purinoceptor during differentiation. J Immunol 157:1371-1380.
10. Ciarcia R, d'Angelo D, Pacilio C, Pagnini D, Galdiero M, Fiorito F, Damiano S, Mattioli E, Lucchetti C, Florio S, Giordano A. 2010. Dysregulated calcium homeostasis and oxidative stress in chronic myeloid leukemia (CML) cells. J. Cell. Physiol 224:443-453.
11. Clarkson B, Strife A. 1993. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 7:1683-17211.
12. Deininger MWN, Goldman JM, Melo JV. 2000. The molecular biology of chronic myeloid leukaemia. Blood 96:3343-3356.
13. Di Virgilio F. 1995. The P2Z purinoceptor: An intriguing role in immunity, inflammation and cell death. Immunol Today 16:524-528.
14. 2+ response amplitude and duration. Nature 386:855-858.
15. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566.
16. Druker BJ, Kantarjian H, Sawyers CL, Resta D, Reese SF, Ford J, Talpaz M. 1999. Activity of an ABL specific tyrosine kinase inhibitor in patients with bcr-abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis. Blood 94:697a (Abstr.).
17. Dubois C, Schlageter MH, De Gentile A, Balitrand N, Toubert ME, Krawice I, Fenaux P, Castaigne S, Najean Y, Degos L. 1994. Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leucemia. Leukemia 8:1750-1757.
18. Gao M, Dong W, Hu M, Yu M, Guo L, Qian L, Guo N, Song L. 2010. GADD45alpha mediates arsenite-induced cell apoptotic effect in human hepatoma cells via JNKs/AP-1-dependent pathway. J Cell Biochem 109:1264-1273.
19. 2+ indicators with greatly improved fuorescence properties. J Biol Chem 260:3440-3450.
20. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J. 1994. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84:3063-3070.
21. Huang N, Wang D, Heppel LA. 1989. Extracellular ATP is a mitogen for 3T3, 3T6, and A431cells and acts synergistically with other growth factors. Proc Natl Acad Sci USA 86:7904-7908.
22. Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, Pages G, Hofman P, Auberger P. 2003. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 17:2160-2162.
23. Karin, 2006. NF-kappaB and cancer: Mechanisms and targets. Mol Carcinog 45:355-361.
24. Keeshan K, Cotter TG, McKenna SL. 2002. High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion. Leukemia 16:1725-1734.
25. Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J, Bataille R. 1990. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw 1:193-201.
26. Klein B, Zhang XG, Lu ZY, Bataille R. 1995. Interleukin-6 in human multiple myeloma. Blood 85:863-872.
27. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. 1995. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248-255.
28. Lowry OH, Rosembrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
29. Lugo TG, Pendergast AM, Muller AJ, Witte ON. 1990. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082.
30. Mayo MW, Baldwin AS. 2000. The transcription factor NF-kappaB: Control of oncogenesis and cancer therapy resistance. Biochim et Biophys Acta 1470:M55-M62.
31. Mitsuyoshi U, Gerrard T, Dharminder C, Yasutaka H, Atsushi O, Steven PT, Robert LS, Kenneth CA. 1997. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 90:279-289.
32. Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y. 2002. An endoplasmic reticulum stress-specific caspase cascade in apoptosis: Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 277:34287-34294.
33. Naka T, Nishimoto N, Kishimoto T. 2002. The paradigm of IL-6: From basic science to medicine. Arthritis Res 4 (Suppl. 3): S233-S242.
34. Neary JT, Kang Y, Bu Y, Ye E, Akong K, Peters CM. 1999. Mitogenic signaling by ATP/P2Y purinergic receptors in astrocytes: Involvement of a calcium-independent protein kinase C, extracellular signal-regulated protein kinase pathway distinct from the phosphatidylinositol-specific phospholipase C/calcium pathway. J Neurosci 19:4211-4220.
35. Ostermann H, Rothenburger M, Mesters RM, van de Loo J, Kienast J. 1994. Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol 88:332-337.
36. Pagnini U, Pacilio C, Florio S, Crispino A, Claudio PP, Giordano A, Pagnini G. 2000. Medroxyprogesterone acetate increases anthracyclines uptake in chronic lymphatic leukaemia cells: Role of nitric oxide and lipid peroxidation. Anticancer Res 20:33-42.
37. Sawyers CL. 1999. Chronic myeloid leukaemia. N Engl J Med 340:1330-1340.
38. Shaulian E, Karin M. 2002. AP-1 as a regulator of cell life and death. Nat Cell Biol 4:E131-E136.
39. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. 2004. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189-218.
40. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. 2008. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 113:1605-1613.
41. van der Poll T, de Jonge E, Levi M. 2001. Regulatory role of cytokines in disseminated intravascular coagulation Semin Thromb Hemost 27:639-651.
42. Vitiello M, D'Isanto M, Galdiero M, Raieta K, Tortora A, Rotondo P, Peluso L, Galdiero M. 2004. Interleukin-8 production by THP-1 cells stimulated by Salmonella enterica serovar Typhimurium porins is mediated by AP-1, NF-kappaB and MAPK pathways. Cytokine 27:15-24.